Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Sky One Makes $8.3 Million Acquisition

publication date: Feb 29, 2008

China Sky One Medical, Inc. will pay $8.3 million to buy Heilongjiang Tianlong Pharmaceutical, Inc. Like China Sky One, Tianlong focuses on external-use pharmaceuticals. According to China Sky One, Tianlong has $8.3 million worth of assets, including inventory, land use rights, GMP-certified manufacturing facilities, production equipment, and an R&D center. The company also boasts a portfolio of 69 approved drugs (in 98 forms), plus 38 new drugs that are awaiting approval from the SFDA. More details...

Stock Symbol: (OTCBB: CSKI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here